A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy

A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy

Abstract CAR-macrophage has promising prospect in treating solid tumors, due to its high infiltration into tumors, and its dual roles in phagocytosis and immune modulation. Here we show the clinical results of CAR-macrophage treatment of two ovarian cancer patients. The CAR-macrophages were produced...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xiumin Li, Xudong Wang, Hao Wang, Donghua Zuo, Jianpo Xu, Yixuan Feng, Dixuan Xue, Li Zhang, Lin Lin, Jin Zhang
Format:	Article
Language:	English
Published:	BMC 2024-11-01
Series:	Journal of Hematology & Oncology
Subjects:	Chimera antigen receptor (CAR) Autologous macrophage Mesothelin Ovarian cancer
Online Access:	https://doi.org/10.1186/s13045-024-01635-5
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Persistence of activated anti‐mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas
by: Sameer Mir, et al.
Published: (2024-11-01)

Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors
by: Jian Ding, et al.
Published: (2023-12-01)

Preclinical evaluation of chimeric antigen receptor T cells targeting the carcinoembryonic antigen as a potential immunotherapy for gallbladder cancer
by: Ernesto Lopez, et al.
Published: (2023-12-01)

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
by: Eugenio Galli, et al.
Published: (2021-10-01)

Néotène, Hybrides et Chimères
by: Marika Moisseeff
Published: (2019-07-01)

High-Dose Chemotherapy and Autologous or Allogeneic Transplantation in Aggressive B-Cell Lymphoma—Is There Still a Role?
by: Michael Daunov, et al.
Published: (2024-10-01)

Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in-human study
by: Tongpeng Xu, et al.
Published: (2024-11-01)

Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas
by: Gohar S. Manzar, et al.
Published: (2025-01-01)

CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA
by: Ugo Testa, et al.
Published: (2024-10-01)

Three-dimensional dynamics of mesothelin-targeted CAR.CIK lymphocytes against ovarian cancer peritoneal carcinomatosis
by: Federica Galvagno, et al.
Published: (2024-11-01)

Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22
by: Scott McComb, et al.
Published: (2024-03-01)

Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies
by: Haiqiong Zheng, et al.
Published: (2024-11-01)

Chimerism in specimens referred to Saurophaganax maximus reveals a new species of Allosaurus (Dinosauria, Theropoda)
by: Andrew Danison, et al.
Published: (2024-12-01)

Preclinical evaluation of immunogenicity and protective efficacy of a recombinant chimeric protein vaccine against visceral leishmaniasis
by: Daniela P. Lage, et al.

Generation of donor organs in chimeric animals via blastocyst complementation
by: T. I. Babochkina, et al.
Published: (2020-12-01)

Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy
by: C. Carcopino, et al.
Published: (2024-12-01)

The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis
by: Jile Liu, et al.
Published: (2025-01-01)

Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects
by: Mehdi Alidadi, et al.
Published: (2024-11-01)

Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma
by: Narendranath Epperla, et al.
Published: (2025-01-01)

Autologous osteoperiosteal transplantation achieves comparable repair effect and superior interface integration to autologous osteochondral transplantation in porcine osteochondral defects
by: Shuai Yang, et al.
Published: (2025-03-01)

Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma
by: Chengcheng Zhang, et al.
Published: (2023-05-01)

Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma
by: Xu Yang, et al.
Published: (2024-12-01)

UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
by: Patrizia Tosi, et al.
Published: (2012-11-01)

UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
by: Patrizia Tosi, et al.
Published: (2012-01-01)

Corrigendum: Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma
by: Chengcheng Zhang, et al.
Published: (2025-01-01)

Comparison of Corneal Epitheliotrophic Factors of Undiluted Autologous Platelet-Rich Plasma and Autologous Serum Eye Drops for Dry Eye Disease
by: Passara Jongkhajornpong, et al.
Published: (2024-12-01)

Identification of TTLL8, POTEE, and PKMYT1 as immunogenic cancer-associated antigens and potential immunotherapy targets in ovarian cancer
by: Esen Yonca Bassoy, et al.
Published: (2025-12-01)

Chimeric antigen receptor T-cell therapy in autoimmune diseases
by: Jie Liu, et al.
Published: (2024-11-01)

Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma
by: Hui-Ju Hsieh, et al.
Published: (2025-03-01)

Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells
by: Pavel Otáhal, et al.
Published: (2016-04-01)

Hepatic T cell lymphoma after chimeric antigen receptor T cell therapy for myeloma
by: Joshua Mehr, et al.
Published: (2024-12-01)

From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy
by: E. Pinto, et al.
Published: (2025-01-01)

New Cases of Teratology, Albinism, Abnormal Pigmentation, Gynandromorphism, and Injury Healing in Scorpions (Arachnida: Scorpiones)
by: Danniella Sherwood, et al.
Published: (2024-11-01)

EAM conditioning regimen followed by autologous hematopoietic Stem Cell Transplantation for relapsed, refractory and high risk lymphomas
by: Mohamed BEKADJA, et al.
Published: (2014-08-01)

Lentivirus-based production of human chimeric antigen receptor macrophages from peripheral blood
by: Ji U Choi, et al.
Published: (2025-01-01)

Clinical outcomes of chimeric antigen receptor T-cell therapy following autologous hematopoietic stem cell transplantation in 38 patients with refractory/relapsed primary or secondary central nervous system lymphoma
by: Jiaying Wu, et al.
Published: (2024-11-01)

Fluctuation of physical function during chimeric antigen receptor T‐cell therapy during rehabilitation intervention: Real‐world data and risk factor analyses
by: Ryota Hamada, et al.
Published: (2024-12-01)

Modified autologous neurosensory retinal transplantation and bevacizumab injection in primary extra-large chronic macular holes
by: Hossein Ashraf, et al.
Published: (2025-06-01)

CRANIOFACIAL DEFORMITIES TREATED BY AUTOLOGOUS FAT TRANSPLANTATION TECHNIQUE: CROSS-SECTIONAL STUDY
by: Cristian Drochioi, et al.
Published: (2024-12-01)

Rapidly Manufactured CAR-T with Conserved Cell Stemness and Distinctive Cytokine-Secreting Profile Shows Improved Anti-Tumor Efficacy
by: Shih-Ting Tsao, et al.
Published: (2024-11-01)